Reference · Tracking · Prices
Every compound has a cited profile that dates its own evidence. The tracker logs each dose against the vial it came from. Prices are read from vendor sites and normalised per milligram, so two listings can actually be compared.
Regulatory lines last checked 1 Sept 2026. We date them because in this category they change quarterly.
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly.
A synthetic 15-amino-acid peptide studied in animals for effects on tendon, ligament and gut tissue repair. No completed human trials.
A once-weekly dual agonist that activates both the GIP and GLP-1 receptors, approved for type 2 diabetes and for weight management.
A synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair. Animal evidence only.
An investigational once-weekly triple agonist acting on the GLP-1, GIP and glucagon receptors. Not approved anywhere.
A GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude.
Per milligram, so vial sizes compare. Read from vendor sites and confirmed by a person.
Last read 13 Oct 2026. Lines show the last few weeks; the full chart has the axis.
Compound profiles with mechanism in plain English, an explicit evidence level, and a regulatory line we date every time we check it.
Browse compoundsReconstitution and dosing arithmetic, with the answer drawn on the barrel you are actually holding. No account needed.
Open the calculatorLog doses against the vial — its compound, vendor, batch and reconstitution date — rather than against an abstract compound. Publish a stack if you want to; nothing is public unless you say so.
Start trackingPer-milligram prices read from vendor sites and confirmed by a person, with the history to show which way they are moving.
See what things costPublished by people using the tracker, under a username they chose. We did not write them and we did not check them, which the pages say plainly.
| Stack | By | Compounds | Weeks | Likes | Copies |
|---|---|---|---|---|---|
| Tendon and soft-tissue repair | mendtherapy | BPC-157, TB-500 | 6 | 2 | — |
| Longevity course with a hard stop | quietlifter | Epitalon, NAD+ | 6 | 1 | — |
| Skin repair and collagen signalling | northlab | GHK-Cu, BPC-157 | 8 | 1 | — |
| Mitochondrial output and NAD salvage | quietlifter | MOTS-c, NAD+ | 8 | 1 | — |
| Sleep depth on a rotating shift | nightshiftrn | DSIP, Ipamorelin | 8 | — | — |
Log a dose in two taps, get the syringe drawn for you, and see how much is still in you. Reminders are scheduled on the phone rather than on a server. Free, on iPhone and Android.
About Pepfolio
News
Chengdu Shengnuo Biopharm went onto FDA Import Alert 66-40 on 19 September 2026 and suspended all peptide ingredient sales to the US. The listing covers all its drugs, not only peptides — and an import alert is a tool that only works on a supplier the FDA can find.
Federal agents searched a North Sioux City building tied to Apex Peptides on 23 September 2026. No charges, no affidavit, and no agency has said what the investigation is about. The FDA is not one of the agencies involved, which is most of what the coverage gets wrong.
Warning letter 731846 objects to both new dietary ingredient notifications BioDrive filed for the peptide in Evolv GLP-1 Biomimetic. Published on 22 September 2026, it cites potential toxicity. The tablet went on sale anyway, and is on sale today.